Why Is DexCom (DXCM) Stock Rocketing Higher Today

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

DXCM Cover Image

What Happened?

Shares of medical device company DexCom (NASDAQ: DXCM) jumped 10.9% in the morning session after the company reported strong second-quarter results and slightly raised its full-year financial outlook. 

The company, which specializes in continuous glucose monitoring systems, posted revenue of $1.31 billion, up 13.1% from the previous year and surpassing analyst expectations. DexCom's profitability also showed significant improvement, with adjusted earnings per share of $0.70, beating estimates by over 15%. 

This was driven by a notable expansion in its operating margin, which climbed to 24.3% from 18.4% in the same quarter last year. Looking ahead, the company nudged its full-year revenue guidance higher to a midpoint of $5.22 billion.

Is now the time to buy DexCom? Access our full analysis report here, it’s free.

What Is The Market Telling Us

DexCom’s shares are quite volatile and have had 15 moves greater than 5% over the last year. But moves this big are rare even for DexCom and indicate this news significantly impacted the market’s perception of the business.

The biggest move we wrote about over the last year was 9 months ago when the stock dropped 14.8% on the news that the company reported underwhelming earnings. The company's revenue grew over 21% year-on-year to $1.21 billion, and its adjusted earnings per share of $0.61 also came in ahead of consensus estimates. DexCom lifted its full-year 2025 revenue forecast to approximately $4.64 billion. Despite these positive metrics, the stock's decline suggests investors were anticipating an even more robust performance and a more substantial guidance increase. The market's negative reaction indicates that the strong quarter was not enough to meet the high expectations priced into the stock, prompting a sell-off.

DexCom is up 23.5% since the beginning of the year, and at $82.20 per share, it is trading close to its 52-week high of $82.26 from August 2025. Despite the year-to-date gain, investors who bought $1,000 worth of DexCom’s shares 5 years ago would now be looking at only $643.00.

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  271.06
+35.56 (15.10%)
AAPL  301.25
-32.18 (-9.65%)
AMD  491.50
+6.11 (1.26%)
BAC  62.16
+0.43 (0.69%)
GOOG  354.18
+20.50 (6.14%)
META  548.42
+9.39 (1.74%)
MSFT  463.43
+12.33 (2.73%)
NVDA  199.22
+4.18 (2.14%)
ORCL  128.69
+1.13 (0.89%)
TSLA  310.82
+1.97 (0.64%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.